论文信息 - Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. - 字舞流文

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

T. Kipps | A. Langerak | A. Kater | Yanwen Jiang | E. Punnoose | M. Verdugo | J. Seymour | J. Wu | C. Owen | M. Mobasher | B. Eichhorst | K. Humphrey | P. Hillmen | M. Boyer | Jue Wang